In preclinical models, inactivation of Rb1 and Trp53 in mouse prostate adenocarcinoma can drive resistance to antiandrogen therapy and promote neuroendocrine transdifferentiation.11, 12. This evidence concerns the gene RB1 and prostate adenocarcinoma.